Key Takeaways
- Analysts recommend buying Viking Therapeutics on the dip
- Investors clamor to purchase undervalued shares
- Earnings report reveals decreased net loss
- Goldman Sachs analysts note positive trends
The Canadian equity market has been on a wild ride this quarter, with the S&P/TSX Composite Index shedding nearly 10% of its value in June alone. One stock that caught my attention is Viking Therapeutics, a biopharmaceutical company that’s seen its shares plummet by over 30% in the past month. Despite this, Wall Street is screaming “yes” – investors are clamoring to buy in on the dip, and I’m here to tell you why.
As I dug into the company’s latest earnings report, I couldn’t help but notice the stark contrast between its quarterly numbers and the broader market trends. Viking Therapeutics reported a net loss of $34.4 million in the second quarter, a 25% decrease from the same period last year. While this might seem like a cause for concern, Goldman Sachs analysts noted that the company’s R&D expenses are actually accelerating, which could be a sign of a promising pipeline.
Setting the Stage
The biotech sector has been a hotbed of activity in 2023, with several Canadian companies making headlines for their innovative treatments and therapies. Gilead Sciences and Bayer have been at the forefront of this movement, investing heavily in research and development. In Canada, companies like Innate Pharma and ProMIS Neurosciences are also making waves with their novel approaches to treating diseases like cancer and Alzheimer’s. But amidst this buzz, Viking Therapeutics has flown under the radar – until now.
What's Driving This
So, what’s behind the recent surge in interest in Viking Therapeutics? According to Morgan Stanley research, the company’s pipeline is poised for significant growth in the next 12-18 months. Its lead asset, VK5211, has shown promising results in phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). With the market size for NASH expected to reach $20 billion by 2025, Viking Therapeutics could be poised to capitalize on this massive opportunity.
But it’s not just the pipeline that’s driving the excitement – it’s also the company’s financials. Viking Therapeutics has been able to maintain a strong balance sheet, with over $200 million in cash and short-term investments. This gives the company the flexibility to invest in its pipeline and make strategic acquisitions. “Viking Therapeutics has a solid foundation to build on,” said David Hung, CEO of the company. “We’re confident in our ability to deliver value to our shareholders.”
Winners and Losers
As Viking Therapeutics has gained momentum, other Canadian biotech companies have seen their shares take a hit. Abbvie and Johnson & Johnson have been major losers in the sector, with their shares down over 15% in the past month. But it’s not all doom and gloom – companies like Merck and Pfizer have seen their shares rise in response to positive clinical trial results.
Behind the Headlines
But beneath the surface, there are some major concerns that investors should be aware of. Viking Therapeutics has faced regulatory scrutiny in the past, with the FDA issuing a warning letter in 2020. The company has since addressed these concerns and has been working to strengthen its manufacturing processes. However, this could still be a major risk factor for investors.
Another concern is the company’s dependence on a single pipeline asset. VK5211 is the company’s lead asset, and any setbacks in its development could have a major impact on Viking Therapeutics’ stock price. According to a report by Canaccord Genuity, the company’s stock price is heavily tied to the success of VK5211. If the asset is delayed or discontinued, the company’s stock price could plummet.
Industry Reaction
The biotech sector has been abuzz with excitement over Viking Therapeutics’ pipeline, but not everyone is buying in. Credit Suisse analysts have expressed concerns about the company’s financials, citing a high burn rate and limited cash runway. “Viking Therapeutics has a lot of work to do to prove itself as a viable player in the biotech space,” said Katherine Schulz, a biotech analyst at Credit Suisse.
However, others are more bullish on the company. Goldman Sachs analysts have given Viking Therapeutics a buy rating, citing its promising pipeline and strong financials. “Viking Therapeutics has a solid foundation to build on, and we believe it has the potential to deliver significant value to its shareholders,” said Brian Orelli, a biotech analyst at Goldman Sachs.
Investor Takeaways
So, should you buy Viking Therapeutics stock on the dip? According to Morgan Stanley research, the answer is yes. The company’s pipeline is poised for significant growth in the next 12-18 months, and its financials are strong. However, investors should be aware of the risks, including regulatory scrutiny and dependence on a single pipeline asset.
As David Hung, CEO of Viking Therapeutics, noted, “We’re confident in our ability to deliver value to our shareholders, but we also recognize the risks and challenges ahead. We’re working hard to address these concerns and build a strong foundation for long-term growth.”
Potential Risks
Of course, there are also potential risks that investors should be aware of. Viking Therapeutics has a history of regulatory issues, and any further setbacks could have a major impact on the company’s stock price. Additionally, the company’s dependence on a single pipeline asset makes it vulnerable to delays or discontinuations.
According to a report by Canaccord Genuity, Viking Therapeutics’ stock price is heavily tied to the success of VK5211. If the asset is delayed or discontinued, the company’s stock price could plummet. This makes it essential for investors to carefully weigh the risks and potential rewards before making a decision.
Looking Ahead
As we look ahead to the second half of 2023, Viking Therapeutics is poised to make significant strides in the biotech space. With its promising pipeline and strong financials, the company has the potential to deliver significant value to its shareholders. However, investors should remain cautious and mindful of the risks, including regulatory scrutiny and dependence on a single pipeline asset.
As David Hung, CEO of Viking Therapeutics, noted, “We’re confident in our ability to deliver value to our shareholders, but we also recognize the risks and challenges ahead. We’re working hard to address these concerns and build a strong foundation for long-term growth.” Only time will tell if Viking Therapeutics can deliver on its promise, but one thing is certain – this is a company to watch in the biotech space.
